Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 11, 2007
Event: Entry into a Material Definitive Agreement.
On September 11, 2007, Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., entered into an Exclusive License Agreement with Stout Medical Group LP ("Stout").
Key Financial Metrics
This filing reports a strategic agreement rather than periodic financial results. Specific revenue, profit, cash flow, or debt figures are not provided in this document.
Agreement Financial Terms:
- Up-front Fee: Payment due upon Stout's delivery of certain V-Stent prototype deliverables.
- Milestone Payments: Design, regulatory, and sales milestones payable beginning in 2008.
- Royalties: Based on net sales of the V-Stent product with minimum annual royalties beginning in 2009.
- Term: The agreement expires in 2027.
Material Changes
The primary material change is the acquisition of an exclusive worldwide license to develop and commercialize Stout's vertebroplasty technology system, known as the "V-Stent." The V-Stent is an expandable titanium cage designed for minimally invasive implantation to treat vertebral body compression fractures.
Outlook, Risks, and Contingencies
Management Commentary: The agreement expands Alphatec Spine's product portfolio in the spine surgery market.
Termination Rights:
- Alphatec Spine may terminate for convenience with 90 days' prior written notice.
- Either party may terminate for a material uncured breach by the other party.
Contingencies: Future payments are contingent upon the achievement of specific design, regulatory, and sales milestones, as well as the generation of net sales.
Investor Verification Checklist
- Verify the specific amount of the up-front license fee and the definition of "deliverables" required for payment.
- Review the detailed schedule of design, regulatory, and sales milestones to assess future cash outflow timing.
- Confirm the royalty rate percentage and the specific calculation of "net sales" in the full agreement.
- Examine the full text of the License Agreement filed as an exhibit to the Form 10-Q for the period ending September 30, 2007.
- Assess the competitive landscape for vertebroplasty technologies to evaluate the commercial viability of the V-Stent.